• Citer

Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

par Kudo, Masatoshi;Finn, Richard R.S.;Edeline, Julien;Cattan, Stéphane;Ogasawara, Sadahisa;Palmer, Daniel D.H.;Verslype, Chris;Zagonel, Vittorina;Fartoux, Laetitia;Vogel, Arndt;Sarker, Debashis;Verset, Gontran ;Chan, Stephen Lam;Knox, Jennifer;Daniele, Bruno;Yau, Thomas;Gurary, Ellen E.B.;Siegel, Abby A.B.;Wang, Anran;Cheng, Ann Lii;Zhu, Andrew Xiuxuan
Référence European journal of cancer, 167, page (1-12)
Publication Publié, 2022-05

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Auteur:	Kudo, Masatoshi; Finn, Richard R.S.; Edeline, Julien; Cattan, Stéphane; Ogasawara, Sadahisa; Palmer, Daniel D.H.; Verslype, Chris; Zagonel, Vittorina; Fartoux, Laetitia; Vogel, Arndt; Sarker, Debashis; Verset, Gontran; Chan, Stephen Lam; Knox, Jennifer; Daniele, Bruno; Yau, Thomas; Gurary, Ellen E.B.; Siegel, Abby A.B.; Wang, Anran; Cheng, Ann Lii; Zhu, Andrew Xiuxuan
Informations sur la publication:	European journal of cancer, 167, page (1-12)
Statut de publication:	Publié, 2022-05
Sujet CREF:	Cancérologie
Mots-clés:	Advanced hepatocellular carcinoma
	Anti-PD-1
	Long-term treatment
	Pembrolizumab
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:doi/10.1016/j.ejca.2022.02.009
	info:pii/S0959804922000843
	info:scp/85127171092
	info:pmid/35364421